Recent Advances in Nanotechnology-Based Strategies for Bone Tuberculosis Management

Yuanrui Luo,Hongwei Chen,Hua Chen,Peng Xiu,Jiancheng Zeng,Yueming Song,Tao Li

DOI: https://doi.org/10.3390/ph17020170

IF: 4.6

2024-01-30

Pharmaceuticals

Abstract:Bone tuberculosis, an extrapulmonary manifestation of tuberculosis, presents unique treatment challenges, including its insidious onset and complex pathology. While advancements in anti-tubercular therapy have been made, the efficacy is often limited by difficulties in achieving targeted drug concentrations and avoiding systemic toxicity. The intricate bone structure and presence of granulomas further impede effective drug delivery. Nano-drug delivery systems have emerged as a promising alternative, offering the enhanced targeting of anti-tubercular drugs. These systems, characterized by their minute size and adaptable surface properties, can be tailored to improve drug solubility, stability, and bioavailability, while also responding to specific stimuli within the bone TB microenvironment for controlled drug release. Nano-drug delivery systems can encapsulate drugs for precise delivery to the infection site. A significant innovation is their integration with prosthetics or biomaterials, which aids in both drug delivery and bone reconstruction, addressing the infection and its osteological consequences. This review provides a comprehensive overview of the pathophysiology of bone tuberculosis and its current treatments, emphasizing their limitations. It then delves into the advancements in nano-drug delivery systems, discussing their design, functionality, and role in bone TB therapy. The review assesses their potential in preclinical research, particularly in targeted drug delivery, treatment efficacy, and a reduction of side effects. Finally, it highlights the transformative promise of nanotechnology in bone TB treatments and suggests future research directions in this evolving field.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

### Problems Addressed by the Paper

This paper primarily explores the latest advancements and potential advantages of nanotechnology in the treatment of osteoarticular tuberculosis. Specifically, the paper aims to address the following key issues:

1. **Complex Pathology and Treatment Challenges of Osteoarticular Tuberculosis**:
- Osteoarticular tuberculosis (a form of extrapulmonary tuberculosis) has an insidious onset and complex pathological characteristics, making early diagnosis difficult.
- Existing anti-tuberculosis drugs struggle to achieve effective local concentrations and are prone to causing systemic toxicity.

2. **Limitations of Existing Treatment Methods**:
- Traditional anti-tuberculosis treatment regimens, including drugs like isoniazid, rifampicin, pyrazinamide, and ethambutol, require long-term medication (12 to 18 months) but suffer from high drug metabolism rates, low bioavailability, and significant side effects.
- While surgical intervention can be used to remove infected tissue and restore bone structure, it has limitations in drug delivery and cannot effectively combine with pharmacological treatment.

3. **Application of Nanotechnology in the Treatment of Osteoarticular Tuberculosis**:
- Nano drug delivery systems can significantly enhance the targeting and bioavailability of drugs at the infection site, reducing systemic side effects.
- Technologies such as mesoporous silica nanoparticles (MSNs) and tetracycline-modified nanoparticles can achieve long-term, sustained drug release locally, improving therapeutic outcomes.
- Nanotechnology can also be combined with bone scaffold materials to achieve precise drug delivery and bone reconstruction at the infection site.

Through these studies, the paper highlights the immense potential of nanotechnology in the treatment of osteoarticular tuberculosis and proposes future research directions to further enhance therapeutic efficacy and patient compliance.